NDC product
Eltrombopag
NDC 0054-0962 · Hikma Pharmaceuticals USA Inc.
Key facts
| Product NDC | 0054-0962 |
|---|---|
| Proprietary name | Eltrombopag |
| Nonproprietary name | Eltrombopag Olamine |
| Substances | ELTROMBOPAG OLAMINE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Hikma Pharmaceuticals USA Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA220033 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Increased Megakaryocyte Maturation [PE], Increased Platelet Production [PE], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Thrombopoietin Receptor Agonist [EPC], Thrombopoietin Receptor Agonists [MoA] and 7 more |
| Marketing start | Apr 24, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: